Table 3 Association of H3K27me3 expression (85% cut-off) with clinicopathological features
Variables | H3K27me3 “low” expression (< 85%) N(%) | H3K27me3 “high” expression (≥ 85%) N(%) | P value |
|---|---|---|---|
Number of cases | 74 (46.3%) | 86 (53.7%) | |
Median age | |||
< 61 years old | 37 (50%) | 39 (45.3%) | 0.557 |
≥ 61 years old | 37 (50%) | 47 (54.7%) | |
Luminal subtype | |||
Luminal A-like | 31 (41.9%) | 35 (40.7%) | 0.878 |
Luminal B-like | 43 (58.1%) | 51 (59.3%) | |
Pathological tumor size | |||
≤ 2 cm (pT1) | 26/71 (36.6%) | 29/77 (37.7%) | 0.817 |
> 2 cm (pT2–4) | 45/71 (63.4%) | 48/77 (62.3%) | |
Pathological nodal status | |||
N0 | 29/73 (39.7%) | 39/80 (48.8%) | 0.262 |
N+ (N1–3) | 44/73 (60.3%) | 41/80 (51.2%) | |
Grade | |||
1 or 2 | 43/74 (58.1%) | 62/86 (72.1%) | 0.069 |
3 | 31/74 (41.9%) | 24/86 (27.9%) | |
Histology | |||
IDC | 62 (83.8%) | 71 (82.6%) | 0.836 |
Other subtypes | 12 (16.2%) | 15 (17.4%) | |
Adjuvant chemotherapy | |||
CT | 29/43 (67.4%) | 34/57 (59.6%) | 0.424 |
No CT | 14/43 (32.6%) | 23/57 (40.4%) | |
Adjuvant endocrine therapy | |||
TMX only | 45/60 (75%) | 48/68 (70.6%) | 0.576 |
TMX + AI | 15/60 (25%) | 19/68 (27.9%) | |